Merck closes in on allergy trifecta with MK-8237 Phase IIb data
This article was originally published in Scrip
With two new allergy drugs nearing potential US FDA approval, Merck & Co said its sublingual dust mite allergy immunotherapy MK-8237 cut nasal symptoms by up to 49% after 24 weeks of once-daily treatment in a Phase IIb clinical trial.
You may also be interested in...
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.